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Epidermal growth factor receptor (EGFR) and KRAS mutations in 
non-small cell lung cancer (nsclc) patients treated with gefitinib
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Suh, Cheolwon; Lee, Jung-Shin 
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Background: Mutations in the tyrosine kinase domain of EGFR have 
been found to be associated with sensitivity of NSCLC to geﬁtinib. We 
analyzed the status of EGFR and KRAS mutations in advanced NSCLC 
to examine their relationship with the response to geﬁtinib. 
Methods: Between December 2001 and December 2004, a total of 199 
NSCLC patients treated with geﬁtinib (250 mg/day) at our institution. 
Sixty patients were assessable for response and had parafﬁn-embedded 
tumor tissue adequate for mutational analysis. Exons 18, 19, and 21 of 
the EGFR gene and exon 2 of the KRAS gene were sequenced. The re-
sults were then correlated with clinical features and outcome, including 
tumor response and patient survival.
Results: EGFR mutations were found in 14 patients (23%). Among 
them, 11 were in three hot-spots (G719, L747-A750, and L858), and 
novel T847A and V851L were observed in three patients. Response 
rate in patients with EGFR mutation was 79% (11 of 14 patients), in 
contrast to 22% (10 of 46 patients) in patients without mutation (P < 
.001). Moreover, these 14 patients with EGFR mutation had signiﬁ-
cantly prolonged time to progression (TTP; 7.7 v 2.4 months; P = .032). 
Patients with EGFR mutation also had better overall survival (OS), 
although it did not reach statistical signiﬁcance (19.2 v 13.6 months; P 
= .25). KRAS mutations were present in 7 of 60 patients (12%) but not 
in any tumors with EGFR mutation. Interestingly, response rates were 
similar for patients with or without KRAS mutation (43% v 34%; P = 
.23). In the multivariate analysis, EGFR mutation and adenocarcinoma 
histology were factors signiﬁcantly associated with better response and 
TTP. 
Conclusions: EGFR mutation is signiﬁcantly associated with a 
response to geﬁtinib and a longer TTP in NSCLC patients. Although re-
sponse rates were not different according to the presence of the KRAS 
mutation, whether KRAS mutational status can be used to predict 
response to geﬁtinib is still not clear. 
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Disease control with a second Epidermal Growth Factor Receptor 
(EGFR) tyrosine kinase inhibitor (TKI) after failure of a first TKI 
in Asian patients with non-small cell lung cancer (NSCLC) 
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Background: Asian NSCLC patients are known to have higher re-
sponse rates to the EGFR TKI geﬁtinib (G) and erlotinib (E). Anecdotal 
reports suggest some activity for a second EGFR TKI after failure of 
the ﬁrst. 
Methods: A retrospective review of the electronic pharmacy records, 
clinical and radiographic records of patients with advanced NSCLC 
at the National University Hospital who received both G and E in the 
previous 2 years was conducted. Objectives were to assess the disease 
control (response/stable disease) of the second TKI after failure of the 
ﬁrst and characterize the clinical, pathological and molecular features 
of patients beneﬁting from a 2nd TKI. 
Results: 14 patients with advanced NSCLC who received a 2nd EGFR 
TKI after progression on the 1st TKI were identiﬁed. Patient character-
istics: Chinese 12, female 10, and non-smokers 13. Histologic subtype: 
adenocarcinoma 7, bronchioloalveolar carcinoma (BAC) 3, squamous-
cell carcinoma 1, NSCLC unspeciﬁed 3. 12 patients received cytotoxic 
chemotherapy with a median of 2 lines, (range 1-5). G and E was 
used as 1st/2nd/3rd/≥4th line treatment in 8/2/2/2 and 0/4/2/8 patients 
respectively. G was used before E in 13 cases and disease control was 
seen in 8/14 (57%) patients. With a 2nd TKI after disease progression, 
disease control was seen 4/14 (28%) patients. Patient characteristics 
were: adenocarcinoma 3, BAC 1, all were never smokers and all 
received and responded to prior G. Median duration of control in these 
4 patients for G was 8 (range 7-12) months, and subsequently to E was 
2.5 (range 2-8) months. Disease control was associated with symptom-
atic improvement. 
Conclusions: This study documents disease control in 28% of Asian 
NSCLC patients treated with a second EGFR TKI after failure of a 
ﬁrst. The molecular basis for these observations is currently being 
investigated.
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Background: Targeting the epidermal growth factor receptor has 
been a novel strategy in treating non-small cell lung cancer (NSCLC). 
Preliminary studies have found cetuximab to be safe in combination 
with platinum-based regimens in NSCLC treatment, and phase III 
investigation is ongoing. This multicenter community-based phase II 
trial was designed to examine the role of cetuximab with a non-plati-
num regimen. 
Methods: The primary endpoint is to assess the objective response 
rate (ORR). Eligibility criteria included: newly diagnosed unresectable 
stage III/IV NSCLC, measurable disease, ECOG PS 0-2, and signed in-
formed consent. Treatment: gemcitabine 1000mg/m2 IV and docetaxel 
30mg/m2 IV days 1, 8, and cetuximab 400mg/m2 day 1, then 250mg/
m2 weekly. Cycles were 21 days, and patients (pts) received 4-6 cycles. 
Pts were restaged every 6 weeks. The trial employed a 2-stage design, 
with a sample size based on achieving an ORR of 25%. 
Results: 27 pts were included in this analysis (n=66 planned). Accrual 
was temporarily suspended due to a higher than anticipated rate of 
cetuximab-based hypersensitivity reactions (HSRs). Baseline charac-
teristics included: median age 68 years (range 47-81); male / female, 
73% / 27%; and ECOG PS 0 / 1 / 2, 50% / 35% / 12% (unknown 3%); 
adenocarcinoma / squamous / large cell / unspeciﬁed, 42% / 23% / 12% 
/ 23%. The ORR was 13% (95% CI 5%-32%). 9 pts (39%) had stable 
disease and 7 pts had progressive disease. 8 pts were not evaluable be-
cause of coming off study due to: comorbidity, 2 pts; treatment-related 
toxicity, 4 pts; and pt request, 2 pts. Grade (G) 3/4 non-hematologic 
toxicity occurring in >2 pts included: fatigue, infection, and hypergly-
cemia, (12% each). G3/4 hematologic toxicity included: leukopenia 
and thrombocytopenia (19% each). There were 5 G3/4 HSRs (19%), 
including a related cardiopulmonary arrest 12 hours post-HSR. 
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Conclusions: Severe HSRs necessitated enrollment suspension at se-
lect southeastern U.S. sites where a higher than expected HSR rate was 
observed. However, this trial continues to accrue at other network sites. 
Additional follow-up is needed to better assess the role of cetuximab 
with this non-platinum regimen in NSCLC.
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Acquired and primary resistant mutations in exon20 of the EGFR 
gene in NSCLC patients who were enrolled in prospective trial for 
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Background: Somatically acquired mutations in the EGFR gene in 
non-small cell lung cancer (NSCLC) are associated with a signiﬁcant 
clinical response to tyrosine kinase inhibitor (TKI), such as geﬁtinib 
or erlotinib. In our retrospective study, cases with EGFR mutations 
(exon19 deletion or exon21 L858R) showed a high sensitivity to 
geﬁtinib, and the patients with sensitive EGFR mutations also tended 
to have a more favorable prognosis than those with wild-type after ge-
ﬁtinib treatment (Lung Cancer 2006;51:71, Br J Cancer 2006;94:896). 
However, most patients with such sensitive mutations in their tumor 
show progression during the TKI treatment. In such resistant tumors, a 
secondary mutation at codon 790 (T790M) in exon20 has been reported 
to be related the resistance to either geﬁtinib or erlotinib.
Methods: Patients with either recurrent disease after undergoing sur-
gery or advanced disease (IIIB or IV) of NSCLC which demonstrated 
EGFR mutations were eligible for the prospective study of treatment 
with geﬁtinib. EGFR mutations in exons 19-21 were examined by our 
previously described screening method and conﬁrmed by direct se-
quencing, and 18 patients were enrolled in this trial whose pretreatment 
tumors had EGFR mutations (11 males and 7 females), after informed 
consent was obtained. Seven patients had a deletion in exon 19, 9 had a 
missense mutation in exon 21 (L858R), 1 had both an exon 19 del and 
L858R, and 1 had an exon19 del and G796A in exon20 (Case 1). Of the 
18 cases, 9 showed PR, 7 showed SD and 2 showed PD. The response 
rate was 50% and disease-control rate was 89%. Of the 9 patients 
with PR, 2 tumor samples (Case 2: lung, Case 3: pleural effusion) that 
became refractory to geﬁtinib were obtained.
Results: Case 1 (71 years-old female): Pretreatment tumor sample 
demonstrated the co-existence of an in-frame deletion in exon19 and 
a missense mutation (G796A) in exon20. In vitro, a stable clone of 
cells bearing the G796A mutation was approximately 50,000-fold less 
sensitive to geﬁtinib in comparison to the cells carrying exon19 dele-
tion. Case 2 (55 years-old male): Pretreatment tumor sample (primary 
lung lesion) had an in-frame deletion in exon19 (del E746-A750). 
Four metastatic lung lesions that became refractory to geﬁtinib were 
obtained, and one of 4 showed a secondary T790M mutation in exon20, 
which was not detected in the pretreatment tumor samples. Case 3 (65 
years-old female): Pretreatment tumor sample (metastatic subclavicu-
lar lymph node) had an in-frame deletion in exon19 (del E746-A750). 
Pleural ﬂuid that became refractory to geﬁtinib was obtained, and the 
sample showed a secondary T790M mutation in exon20. 
Conclusions: Our results suggest that T790M and G796A mutations 
in exon20 are useful biomarker for acquired and primary resistance 
to TKI (geﬁtinib). Because all refractory tumors do not always have 
T790M mutation, other mechanism in addition to T790M might play a 
role in the acquisition of resistant to geﬁtinib.
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Sensitive PCR method detects EGFR exon19 deletions in NSCLC
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Purpose: Recently, somatic mutations in Epidermal Growth Factor Re-
ceptor (EGFR) exon 18-21 have been identiﬁed in non-small cell lung 
carcinomas that predict response to Tyrosine Kinase Inhibitors (TKI), 
but only exon 19 deletions predict survival. As the direct sequencing 
is time consuming and can be technically difﬁcult and costly, we have 
developed a simple, PCR-based method to detect exon 19 deletion mu-
tations as a potentially cost effective and sensitive method for identify-
ing those NSCLC patients for whom TKI treatment may offer survival 
beneﬁt.
Materials and Methods: A total of 9 NSCLC lines and 73 clinical 
tumor samples from Japanese patients which were treated with geﬁtinib 
were tested in this study. Five cell lines (HCC827, H1650, HCC2279, 
HCC4006 and H3255) have known mutations in EGFR TK domain, 
and 4 cell lines (H157, H460, H520 and A549) have no known muta-
tions and are resistant to geﬁtinib. Formalin Fixed Parafﬁn Embedded 
(FFPE) sections from clinical samples and cytology preparations were 
microdissected under stereoscopic microscopy. A semi-nested PCR was 
employed to amplify exon 19 in which the ﬁrst round primers were 
placed in the introns encompassing the whole of exon 19. Template 
from the ﬁrst round PCR was ampliﬁed with two additional primer sets 
(the screening PCR and delE746_A750 speciﬁc PCR). The screening 
PCR primers encompass all known exon 19 deletions and delE746_
A750 speciﬁc PCR primers were designed to skip delE746-750A. 
Results: Successful detection of known mutations was achieved in 
HCC827 and HCC2279 with as little as 40 picograms of puriﬁed DNA 
and at mutant to wild type DNA ratios (M/W) of 1/600. DNA from a 
single cell from a cytology preparation could be ampliﬁed by this assay. 
The assay detected variations in the M/W ratio even in cell lines with 
deletion. All deletions present in cell lines and none of the non-mutant 
lines were positive by this assay (100% sensitivity and speciﬁcity). 
In 73 clinical cases, the assay detected deletion mutations in 25 cases 
(34.2%). Five of 25 cases were not detected by sequencing and this 
assay thus was more sensitive in clinical samples than sequencing. Log 
rank analysis indicated signiﬁcant survival difference between patients 
with and without exon 19 deletion (p=0.017).
Conclusions: PCR-based EGFR exon 19 deletion assay is sensitive 
for all known mutations in exon 19. It can be performed on parafﬁn 
embedded tissue and cytology samples rapidly and may be suitable for 
economical large scale screening in clinical samples. 
